Raremark

Xperiome, formerly known as Raremark, operates as a global healthtech company with a specific focus on the rare disease sector. The firm was established in 2007 by Julie Walters and Peter Coe in London, United Kingdom. Walters, who holds a degree in molecular genetics and has a background in journalism, was motivated to start the company after several family members were affected by rare health conditions, highlighting the need for a centralized resource of information and shared patient experiences. Alex Garner, who began with the company at its inception and holds the role of Chief Operating Officer, has been instrumental in the development of the company's technology platforms.

The company's core mission is to accelerate the development of therapies for rare diseases by connecting pharmaceutical companies with patients. Xperiome's business model is structured around providing services to the biopharmaceutical industry, contract research organizations (CROs), and other life science partners. Revenue is generated through several streams: providing high-value insights from patient data via surveys and studies, referring suitable patients for clinical trials, and offering brand positioning services through targeted content. This model addresses a critical bottleneck in drug development, as patients with rare diseases are often difficult to locate.

Xperiome operates a patient-facing platform called Raremark, which serves as a community and knowledge hub for individuals and caregivers affected by any of the over 7,000 known rare conditions. This platform allows members to access information, connect with others who have similar experiences, and learn about opportunities to participate in medical research. For its corporate clients, Xperiome leverages this engaged patient community to offer patient recruitment for both traditional and decentralized clinical trials, and to provide real-world data that helps in evaluating treatment effectiveness and informing marketing strategies. The Xperiome platform utilizes machine learning and behavioral science to analyze the collected patient experiences, creating a comprehensive knowledge base that offers a 360-degree view of patient journeys. This data-driven approach enables the company to match research-ready members with clinical and real-world studies more efficiently.

Keywords: rare disease, healthtech, patient recruitment, real-world data, clinical trials, patient community, biopharmaceutical services, life sciences, drug development, patient insights, real-world evidence, patient advocacy, orphan drugs, CRO services, patient-centric, health data, medical research, clinical study matching, patient experience, data-driven insights